Open access
Oct 2026
Effects of imeglimin on liver enzymes and body composition in patients with MASLD and type 2 diabetes: a pilot study
Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM), yet effective pharmacological options remain limited. Imeglimin, a novel antidiabetic agent targeting mitochondrial bioenergetics, has shown potential hepatoprotective effects in precli...
Kaede Fujita, Takanobu Iwadare, Takefumi Kimura et al.
· Diabetology International · 0 citations